Features and properties of nabumetone

Drugs

Volumn 59, Issue SPEC. ISS. 1, 2000, Pages 25-33

  Davies, Neal M ^a   McLachlan, Andrew J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

6 METHOXY 2 NAPHTHYLACETIC ACID; CYCLOOXYGENASE 2; NABUMETONE; NONSTEROID ANTIINFLAMMATORY AGENT; ALKANONE;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTHROPATHY; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY DISEASE; OSTEOARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATIC DISEASE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BUTANONES; HUMANS; RHEUMATIC DISEASES;

EID: 0034061194     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200059991-00004     Document Type: Review

References (49)

1. Heller CA, Ingelfinger JA, Goldman P. Nonsteroidal anti-inflammatory drugs and aspirin: analyzing the scores. Pharmacotherapy 1985; 5: 30-8
2. Walker JS, Sheather-Reid RB, Carmody JJ, et al. Nonsteroidal antiinflammatory drugs in rheumatoid arthritis and osteoarthritis: support for the concept of 'responders' and 'non-responders'. Arthritis Rheum 1997; 40: 1944-51
3. Friedel HA, Todd PA. Nabumetone: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in rheumatic diseases. Drugs 1988; 35 (5): 504-24
4. Friedel HA, Langtry HD, Buckley MM. Nabumetone: a reappraisal of its pharmacology and therapeutic use in rheumatic diseases. Drugs 1993; 45: 131-6
5. Davies NM. Clinical pharmacokinetics of nabumetone. The dawn of selective cyclo-oxygenase-2 inhibition? Clin Pharmacokinet 1997; 33: 403-16
6. Jeremy JY, Mikhailidis DP, Barradas MA. The effect of nabumetone and its principal active metabolite on in vitro human gastric mucosal prostanoid synthesis and platelet function. Br J Rheumatol 1990; 29: 116-9
7. Haddock RE, Jeffery DJ, Lloyd JA, et al. Metabolism of nabumetone (BRL 14777) by various species including man. Xenobiotica 1984; 14: 327-37
8. Goudie AC, Gaster LM, Lake AW, et al. 4-(6-methoxy-2-naphthyl)butan-2-one and related analogues, a novel structural class of antiinflammatory compounds. J Med Chem 1978; 21: 1260-4
9. Nandi KL, Corless D, Undre NA. A study of the pharmacokinetics, effectiveness, and tolerance of nabumetone, a novel anti-inflammatory drug, in elderly patients. Roy Soc Med Int Sym Ser 1985; 69: 163-72
10. Torre D, Sampietro C, Maggiolo F. Blood and tissue fluid levels of a new non-steroidal anti-inflammatory preparation of nabumetone. J Int Med Res 1987; 15: 368-73
11. Mangan FR, Flack JD, Jackson D. Preclinical overview of nabumetone : pharmacology, bioavailability, metabolism and toxicology. Am J Med 1987; 83 Suppl. 4B: 6-10
12. Davies NM, Wallace JL. Non-steroidal antiinflammatory drug-induced gastrointestinal toxicity: new insights into an old problem. J Gastroenterol 1997; 32: 127-33
13. Blower P. The science - equivalent efficacy and diminished risk. Eur J Rheum Inflamm 1991; 11: 37-57
14. Moreno-Sanchez R, Bravo C, Vasquez C, et al. Inhibition and uncoupling of oxidative phosphorylation by nonsteroidal anti-inflammatory drugs: study in mitochondria, submitochondrial particles, cells, and whole heart. Biochem Pharmacol 1999; 57: 743-52
15. Bianchi Porro G, Montrone F, Petrillo M, et al. Gastroduodenal tolerability of nabumetone versus naproxen in the treatment of rheumatic patients. Am J Gastroenterol 1995; 90: 1485-8
16. Roth SH, Tindall EA, Jain AK, et al. A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med 1993; 153: 2565-71
17. Voss GD. GI bleeding associated with nabumetone. Am J Hosp Pharm 1994; 51: 2506-8
18. Brett MA, Buscher G, Ellrich E, et al. Nabumetone: evidence for the lack of enterohepatic circulation of the active metabolite 6-MNA in humans [short communication]. Drugs 1990; 40 Suppl. 5: 67-70
19. Sigthorsson G, Tibbie J, Hayllar J, et al. Intestinal permeability and inflammation in patients on NSAIDs. Gut 1998; 43: 506-11
20. Tibbie JA, Sigthorsson G, Foster R, et al. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut 1999; 45: 362-6
21. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993; 268: 6610-4
22. Laneuville O, Breuer DK, Dewitt DL, et al. Differential inhibtion of human prostaglandin endoperoxide H synthases-1 and -2 by non-steroidal anti-inflammatory drugs. J Pharmacol Exp Ther 1994; 271: 927-34
23. Riendeau D, Percival MD, Boyce S, et al. Biochemical and pharmacological profile of a tetrasubsituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol 1997; 121: 105-17
24. Day RO, McLachlan AJ, Graham GG, et al. Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid. Clin Pharmacokinet 1999; 36 (3): 191-210
25. Bourke B, Undre NA, Thawley AR. An investigation into the penetration of nabumetone and its metabolites into synovial fluid in patients with rheumatoid arthritis. Roy Soc Med Int Sym Ser 1985; 69: 31-5
26. Freeman AM, Undre NA, Thawley AR, et al. Plasma and synovial fluid concentrations of nabumetone and BRL 10720 in patients given nabumetone. Roy Soc Med Int Sym Ser 1984; 69: 40-2
27. Miehlke RK, Schneider S, Sorgel F, et al. Penetration of the active metabolite of nabumetone into synovial fluid and adherent tissue of patients undergoing knee joint surgery. Drugs 1990; 40 Suppl. 5: 57-61
28. Dingle JT. The effects of NSAID on the matrix of human articular cartilages. Z Rheumatol 1999; 58: 125-9
29. Giordano N, Senesi M, Battisti E, et al. Tolerability of nabumetone: a pilot in vitro study showing absence of injury to articular cartilage. Int J Tissue React 1996; 18: 105-8
30. Jenner PN, Johnson ES. Review of the experience with nabumetone in clinical trials outside of the United States. Am J Med 1987; 83 (4B): 110-4
31. Movilia P, Restelli L, Miriano F, et al. Analgesic activity of nabumetone in postoperative pain [short communication]. Drugs 1990; 40 Suppl. 5: 71-4
32. Coaccioli S, Allegra A, Di Cato L, et al. Clinical efficacy and tolerance of nabumetone in articular and non-articular rheumatic disorders: personal experience during 12 weeks of treatment. Panminerva Med 1998; 40: 110-5
33. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999; 106: 13S-24
34. Blackwell E, Loughlin K, Dumler F, et al. Nabumetone-associated interstitial nephritis. Pharmacother 1995; 15: 669-72
35. Arnoff GR. Therapeutic implications associated with renal studies of nabumetone. J Rheumatol 1992; Suppl. 36: 25-31
36. Cangiano JL, Figueroa J, Palmer R. Renal hemodynamic effects of nabumetone, sulindac, and placebo in patients with osteoarthntis. Clin Ther 1999; 21: 503-12
37. Cook ME, Wallin JD, Thakur VD, et al. Comparative effects of nabumetone, sulindac, and ibuprofen on renal function. J Rheumatol 1997; 24: 1137-44
38. Giannessi D, Lazzerini G, Filipponi P, et al. Effects of nabumetone, a new non-steroidal anti-inflammatory drug, on urinary prostaglandin excretion in man. Pharmacol Res 1993; 28: 229-41
39. Freed MI, Audet PR, Zariffa N, et al. Comparative effects of nabumetone, sulindac, and indomethacin on urinary prostaglandin excretion and platelet function in volunteers. J Clin Pharmacol 1994; 34: 1098-108
40. Brier ME, Aronoff GR. Multiple dose kinetics of nabumetone in renal impairment. Clin Res 1990; 38: 520A
41. Hamdy RC, Price JD, Undre NA. The pharmacokinetics of nabumetone in elderly patients. Roy Soc Med Int Sym Ser 1985; 69: 173-9
42. Boelaert JR, Jonnaert HA, Daneels RF, et al. Nabumetone pharmacokinetics in patients with varying degrees of renal impairment. Am J Med 1987; 83 (4B): 107-9
43. Schror K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 1997; 23: 349-56
44. Grossman CJ, Wiseman J, Lucas FS, et al. Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDS and COX 2 inhibitors. Inflamm Res 1995; 44: 253-7
45. Cipollone F, Ganci A, Panara MR, et al. Effects of nabumetone on prostanoid biosynthesis in humans. Clin Pharmacol Ther 1995; 58: 335-451
46. Schnitzer TJ, Donahue JR, Toomey EP, et al. Effect of nabumetone on hemostasis during arthroscopic knee surgery. Clin Ther 1998; 20: 110-24
47. Knijff-Dutmer EA, Martens A, vd Laar MA. Effects of nabumetone compared with naproxen on platelet aggregation in patients with rheumatoid arthritis. Ann Rheum Dis 1999; 58: 257-9
48. al Balla S, al Momen Ak, al Arfaj H, et al. Interaction between nabumetone - a new non-steroidal anti-inflammatory drug - and the haemostatic system ex vivo. Haemostasis 1990; 20: 270-5
49. Pardo A, Garcia-Losa M, Fernandez-Pavon A, et al. A placebocontrolled study of interaction between nabumetone and acenocoumarol. Br J Clin Pharmacol 1999; 47: 441-4